Chiasma, Inc. logo
Chiasma, Inc. CHMA

Chiasma, Inc. Net Debt 2011-2026 | CHMA

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Chiasma, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-15.5 M -25.3 M 16 M 38.4 M 21.6 M -35.6 M -35.5 M -12.8 M - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
38.4 M -35.6 M -6.08 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
455 M $ 9.13 -0.76 % $ 591 M usaUSA
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.91 2.42 % $ 6.69 M chinaChina
Edesa Biotech Edesa Biotech
EDSA
-7.74 M $ 15.52 -2.39 % $ 49.6 M usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
-83 M $ 22.47 1.19 % $ 3.72 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
-24.8 M $ 2.24 0.9 % $ 62.5 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
-25.6 M $ 2.26 0.22 % $ 144 M usaUSA
Galapagos NV Galapagos NV
GLPG
-1.29 B $ 28.07 0.75 % $ 2.69 B belgiumBelgium
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
5.36 B $ 8.2 3.6 % $ 6.83 B spainSpain
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
-608 M $ 31.01 -0.13 % $ 1.78 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
ImmuCell Corporation ImmuCell Corporation
ICCC
3.77 M $ 8.44 - $ 76.2 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
-32.3 M $ 1.95 -1.77 % $ 152 M germanyGermany
Immuron Limited Immuron Limited
IMRN
-21.9 M $ 0.83 3.44 % $ 6.55 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
-3.06 B $ 98.87 -0.23 % $ 19.3 B usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
-8.52 M $ 0.71 1.28 % $ 1.74 M canadaCanada
INmune Bio INmune Bio
INMB
-23.7 M $ 1.35 1.5 % $ 33.4 M usaUSA
Innoviva Innoviva
INVA
-293 M $ 23.13 0.35 % $ 1.56 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
533 K - -2.5 % $ 5.88 M usaUSA
BioNTech SE BioNTech SE
BNTX
-973 M $ 104.54 2.92 % $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
Jaguar Health Jaguar Health
JAGX
116 K $ 7.55 -4.13 % $ 17.6 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
-55.5 M $ 26.67 -0.02 % $ 1.44 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
-120 M $ 1.43 -4.03 % $ 235 M franceFrance
Kamada Ltd. Kamada Ltd.
KMDA
-70.2 M $ 8.15 0.49 % $ 260 M israelIsrael
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
-5.43 M $ 13.24 6.56 % $ 1.75 B australiaAustralia
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
-71 M $ 223.98 -0.39 % $ 4.1 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-3.5 M $ 3.22 7.69 % $ 5.3 M israelIsrael
Liquidia Corporation Liquidia Corporation
LQDA
-72.5 M $ 38.39 0.62 % $ 3.3 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Applied Therapeutics Applied Therapeutics
APLT
-49.4 M - - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
-75.5 M $ 4.08 0.74 % $ 436 M usaUSA